TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00621985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
Study: NCT03379168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfragmented Adipose Tissue (Lipogems)
Description: Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Cortisone is a standard of care injection to reduce joint inflammation.
Study: NCT03017612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
Study: NCT03214029

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac troponin testing
Description: Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
Study: NCT02898753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-1221
Description: VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-1221
Description: VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-1221
Description: VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VAL-1221
Description: VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RhGAA
Description: Active comparator
Study: NCT01782235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05269979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention of hip fractures
Description: Physical exercise and lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
Study: NCT03756506

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel Microbicidal Liquid Polymer
Description: The polymer is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
Study: NCT02076373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human Erythropoietin
Description: i.v. administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: i.v. administration
Study: NCT03667794

Intervention type: DIAGNOSTIC_TEST
Intervention: body plethysmography
Description: measurement of conventional lung function parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: body plethysmography
Description: measurement of conventional lung function parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: impulse oscillometry
Description: measurement of central and peripheral airway resistance

Intervention type: DIAGNOSTIC_TEST
Intervention: impulse oscillometry
Description: measurement of central and peripheral airway resistance

Intervention type: DIAGNOSTIC_TEST
Intervention: impulse oscillometry
Description: measurement of central and peripheral airway resistance

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout
Description: measurement of ventilation heterogeneity

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout
Description: measurement of ventilation heterogeneity

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout
Description: measurement of ventilation heterogeneity
Study: NCT01253967

Intervention type: PROCEDURE
Intervention: Collection of stool samples
Description: Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.

Intervention type: PROCEDURE
Intervention: Collection of stool samples
Description: Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.

Intervention type: PROCEDURE
Intervention: Collection of stool samples
Description: Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.

Intervention type: OTHER
Intervention: Health economics questionnaire
Description: For a subset of subjects, additional economic data will be gathered by completing a questionnaire

Intervention type: OTHER
Intervention: Health economics questionnaire
Description: For a subset of subjects, additional economic data will be gathered by completing a questionnaire

Intervention type: OTHER
Intervention: Health economics questionnaire
Description: For a subset of subjects, additional economic data will be gathered by completing a questionnaire
Study: NCT03050606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Exercises performed on the mat and apparatus, following the six principles of the Pilates method. The exercises will be performed in three levels of difficulty: basic, intermediate and advanced, according to the capacity of the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic
Description: Aerobic exercise will be carried out individually on treadmills or stationary bikes. The intensity of the training will be mild to moderate (57% to 76% of the maximal heart rate monitored by the frequencymeter).
Study: NCT03823898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: Two supervised exercise sessions per week from months 4 to 16

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention from baseline to 4 months
Description: Lifestyle intervention from baseline to 4 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention from baseline to 4 months
Description: Lifestyle intervention from baseline to 4 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention from baseline to 4 months
Description: Lifestyle intervention from baseline to 4 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly behavioral sessions
Description: Monthly behavioral sessions consisted of lifestyle interactive sessions will take place monthly and covered and followed contents that were addressed during the first 4 months of the study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly behavioral sessions
Description: Monthly behavioral sessions consisted of lifestyle interactive sessions will take place monthly and covered and followed contents that were addressed during the first 4 months of the study
Study: NCT02408484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octafibrin
Description: Plasma-derived Fibrinogen concentrate
Study: NCT03671642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-ICG
Description: Quantitative perfusion assessment with indocyanine green on a touch screen tablet

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: White light perfusion assessment
Description: Traditional visual perfusion assessment in white light

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence angiography
Description: Perfusion assessment with fluorescence angiography - without quantification
Study: NCT02054936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban (Xarelto)
Description: To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin (Coumadin)
Description: To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
Study: NCT00488059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 90 mg SC twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background ARV
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background ARV
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Integrase inhibitor
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Integrase inhibitor
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 180 mg SC once daily
Study: NCT04762264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProFlor inguinal hernia device
Description: Device follow up after inguinal hernia repair with ProFlor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProFlor inguinal hernia device
Description: Device follow up after inguinal hernia repair with ProFlor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProFlor inguinal hernia device
Description: Device follow up after inguinal hernia repair with ProFlor
Study: NCT04053218

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Exercise plus omega-3 supplement
Description: Supervised aerobic exercise and omega-3 supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil placebo
Study: NCT02625389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol® Ultra Fluid with surgical glues
Description: Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
Study: NCT03329664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cell
Description: Immune-cell therapy with CIK cells

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy AND/OR Radiation Therapy
Description: Routine treatments for colon cancer patients according to their stage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy AND/OR Radiation Therapy
Description: Routine treatments for colon cancer patients according to their stage
Study: NCT03238079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10% IGIV
Description: 300-900 mg/kg
Study: NCT01665898

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Biopsy forceps
Description: removal of polyps using cold biopsy forceps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold snare biopsy
Description: Removal of colon polyps using cold snare biopsy
Study: NCT03408288

Intervention type: OTHER
Intervention: Hemapoche
Description: Use of Hemapoche scale to assess hematuria in reference samples

Intervention type: OTHER
Intervention: Hemapoche
Description: Use of Hemapoche scale to assess hematuria in reference samples

Intervention type: OTHER
Intervention: Hemastick
Description: Use of Hemastick scale to assess hematuria in reference samples

Intervention type: OTHER
Intervention: Hemastick
Description: Use of Hemastick scale to assess hematuria in reference samples

Intervention type: OTHER
Intervention: Color description
Description: Describe color of reference sample

Intervention type: OTHER
Intervention: Color description
Description: Describe color of reference sample
Study: NCT04771104

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid Challenge (AAC)
Description: The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amino Acid Challenge (AAC)
Description: The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.
Study: NCT04583345

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires: Physical therapists ask questions these assess quality of life, anxiety and depression, physical activity level.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires: Physical therapists ask questions these assess quality of life, anxiety and depression, physical activity level.
Study: NCT00662727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
Description: Energy Density - 0.09 mJ/mm2

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04433065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrepid™ TTVR System
Description: Device: Intrepid™ TTVR System
Study: NCT05028881

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling for determining antibody responses
Study: NCT05119153

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo designed to mimic coffee color.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Light Roasted Coffee
Description: 12 oz light roast coffee

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium Roasted Coffee
Description: 12 oz medium roast coffee

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Roasted Coffee
Description: 12 oz dark roast coffee
Study: NCT02074917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomical ACL reconstruction
Description: Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomical ACL reconstruction
Description: Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.
Study: NCT02677714

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-rhAnnexin V-128
Description: Kit for the preparation of 99mTc-rhAnnexin V-128
Study: NCT03639454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction.
Study: NCT04100863

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study: NCT02930967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous CSR T
Description: Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
Study: NCT06425497

Intervention type: OTHER
Intervention: The dosage of dnDSA
Description: Flow cytometric analysis using FlowPRA Screening Test and/or Luminex Single Antigen Beads class I and II- IgG (cut- positivity off = MFI\> 1000)
Study: NCT01796938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide tablet
Description: Single dose of 100 mg Lacosamide tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide tablet
Description: Single dose of 100 mg Lacosamide tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide tablet
Description: Single dose of 100 mg Lacosamide tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide tablet
Description: Single dose of 100 mg Lacosamide tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide tablet
Description: Single dose of 100 mg Lacosamide tablet
Study: NCT02996214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Liposome
Description: Paclitaxel liposome injection 175 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
Study: NCT03131544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Guided Transrectal Periuretheral Transitional Zone Ablation
Description: Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
Study: NCT04831463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasising Health Awareness Program for Immigrant Men
Description: The IHAPIM program is a health promotion intervention. The aim of intervention improve health perception and responsibilitiy
Study: NCT03844217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macimorelin 0.5mg/kg body weight
Description: oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macimorelin 0.75mg/kg body weight
Description: oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin
Study: NCT02465294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention
Description: All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
Study: NCT04530630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIKTARVY 50Mg-200Mg-25Mg Tablet
Description: A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.
Study: NCT02124668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: oral
Study: NCT02465294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention
Description: All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.